Estadístiques de Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: Findings from the PACIFIC-R study
Visites totals
| views | |
|---|---|
| Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: Findings from the PACIFIC-R study | 65 |
Visites totals per mes
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 1 |
| February 2025 | 2 |
| March 2025 | 0 |
| April 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| Girard_jto_trea.pdf(legacy) | 182 |
| Girard_jto_trea.pdf | 48 |
Vistes principals per país
| views | |
|---|---|
| United States | 51 |
| Japan | 4 |
| Belgium | 3 |
| Spain | 2 |
| Australia | 1 |
| China | 1 |
| India | 1 |
| Malaysia | 1 |
| Netherlands | 1 |
Visites principals per ciutat
| views | |
|---|---|
| Ann Arbor | 6 |
| Boardman | 6 |
| Mountain View | 5 |
| San Ramon | 5 |
| Tokyo | 4 |
| Tustin | 4 |
| Ashburn | 2 |
| Barcelona | 2 |
| Fairfield | 1 |
| Fremont | 1 |
| Menlo Park | 1 |
| Mumbai | 1 |
| Petaling Jaya | 1 |
| Richardson | 1 |
| Sacramento | 1 |
| Shenzhen | 1 |